To a patient, a pharmacy shelf is just a place where medicines wait. To a pharmacist, it is the final link in a long quality chain that starts at the manufacturer. If storage, stock rotation or recall handling fails at this last step, every earlier quality control is undermined.
In my work at Amavita in Bülach and Coop Vitality in Feuerthalen, inventory management has always been part of regulatory compliance. This article describes the three pillars of that hidden quality system and how they mirror pharmaceutical quality assurance.
Pillar 1: Storage conditions and the cold chain
Every medicine has defined storage conditions, stated in its product information (Medicinal Products Ordinance [VAM], 2018). The two most common are room temperature, typically not above 25 °C, and refrigeration at 2–8 °C.
Refrigerated products include vaccines, insulins, many biologics and some eye drops. They can lose potency if they become too warm, and some are damaged irreversibly by freezing (Matthias et al., 2007). The loss is usually invisible: a damaged vaccine looks exactly like an intact one.
Good practice includes:
- Continuous temperature monitoring with calibrated data loggers, not just a thermometer read once a day (European Commission, 2013).
- Alarms that alert staff when temperatures move outside the range.
- Correct loading of refrigerators, keeping products away from walls and cooling elements where freezing can occur.
- Documented checks, so the temperature history can be shown during an inspection.
- Cold chain on receipt, checking that refrigerated deliveries arrived within range and moving them into storage immediately.
Handling a temperature excursion
When a refrigerator goes out of range, a structured response protects patients:
- Quarantine the affected products and label them clearly as "do not use".
- Document the maximum or minimum temperature reached and the duration.
- Assess stability using product information or by contacting the manufacturer.
- Decide whether products can be released, and document the reason.
- Correct and prevent, for example repairing equipment or changing the alarm set-up.
This is the same deviation logic used in pharmaceutical warehouses and manufacturing sites (International Council for Harmonisation [ICH], 2008).
Pillar 2: Expiry management and stock rotation
Expired medicines may lose effectiveness, and in rare cases degradation products can be harmful. Dispensing an expired product is also a regulatory breach (Therapeutic Products Act [TPA], 2000).
Pharmacies use FEFO (first expired, first out) rather than simply first in, first out. Products with the shortest remaining shelf life are placed at the front and used first.
Regular expiry checks, often monthly, identify short-dated stock. Pharmacy software helps, but physical checks remain important because errors in the system do happen.
In-use shelf life adds another layer. Once opened, products such as eye drops, insulin pens and oral solutions may have a much shorter usable life. Patients need to be told this clearly at dispensing.
Pillar 3: Recalls and traceability
When a manufacturer or Swissmedic identifies a quality defect, a recall may follow. Recalls are classified by urgency and by how far they reach (European Commission, 2013): to wholesalers, to pharmacies and hospitals, or to patients.
A pharmacy recall process typically includes:
- reading the recall notice carefully and identifying the affected product and batch numbers;
- checking all storage locations, including the robot, back stock and refrigerators;
- removing affected stock to a quarantine area and documenting quantities;
- returning stock according to instructions;
- contacting patients when the recall reaches patient level, using dispensing records;
- documenting each step for traceability.
Traceability depends on batch numbers. A recall reaching patient level is only effective if the pharmacy can identify who received the affected batch.
The industry parallel
The same three pillars exist throughout the pharmaceutical supply chain, governed by Good Distribution Practice (GDP; European Commission, 2013; Medicinal Products Licensing Ordinance [AMBV], 2018):
| Pharmacy practice | Pharmaceutical quality assurance |
|---|---|
| Fridge monitoring and excursion handling | Temperature mapping, qualified storage, deviation management |
| FEFO and expiry checks | Shelf-life management and stock status control |
| Recall handling and patient contact | Recall procedures, mock recalls and authority notification |
| Quarantine of suspect stock | Quarantine, release and rejection status in the warehouse system |
The scale and systems differ, but the logic is the same: protect product quality at every step and be able to prove it.
Why this matters to employers
Quality assurance in logistics and distribution needs people who understand why each control exists, not only how to perform it. My experience managing pharmaceutical inventory, storage and regulatory compliance in Swiss pharmacies gives me a practical foundation for QA roles in supply chain and distribution.
Key takeaways
- Storage, stock rotation and recalls form the last link in the medicine quality chain.
- Temperature excursions follow deviation logic: quarantine, document, assess, decide, prevent.
- Batch-level traceability makes recalls effective.
References
European Commission. (2013). Guidelines of 5 November 2013 on good distribution practice of medicinal products for human use (2013/C 343/01). Official Journal of the European Union, C 343, 1–14.
International Council for Harmonisation. (2008). Pharmaceutical quality system Q10. https://www.ich.org
Matthias, D. M., Robertson, J., Garrison, M. M., Newland, S., & Nelson, C. (2007). Freezing temperatures in the vaccine cold chain: A systematic literature review. Vaccine, 25(20), 3980–3986. https://doi.org/10.1016/j.vaccine.2007.02.052
Medicinal Products Licensing Ordinance [AMBV] of 14 November 2018, SR 812.212.1 (Switzerland). https://www.fedlex.admin.ch
Medicinal Products Ordinance [VAM] of 21 September 2018, SR 812.212.21 (Switzerland). https://www.fedlex.admin.ch
Therapeutic Products Act [TPA] of 15 December 2000, SR 812.21 (Switzerland). https://www.fedlex.admin.ch
Member discussion